Calyxt (CLXT) Receives Daily Media Impact Rating of 0.05

Headlines about Calyxt (NASDAQ:CLXT) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Calyxt earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.2470685323456 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Calyxt (NASDAQ CLXT) opened at $26.05 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 12.41 and a quick ratio of 12.41. Calyxt has a fifty-two week low of $9.26 and a fifty-two week high of $31.89.

Calyxt (NASDAQ:CLXT) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.35). Calyxt had a negative net margin of 5,969.52% and a negative return on equity of 101.69%. analysts predict that Calyxt will post -1.07 EPS for the current fiscal year.

CLXT has been the subject of a number of recent research reports. Zacks Investment Research downgraded Calyxt from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. BMO Capital Markets assumed coverage on Calyxt in a report on Monday, October 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Jefferies Group upped their price objective on Calyxt to $27.00 and gave the company a “buy” rating in a report on Wednesday, November 1st. Citigroup dropped their price objective on Calyxt from $27.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, November 16th. Finally, Ladenburg Thalmann Financial Services assumed coverage on Calyxt in a report on Wednesday, December 20th. They issued a “buy” rating and a $34.25 price objective for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $29.05.

TRADEMARK VIOLATION NOTICE: “Calyxt (CLXT) Receives Daily Media Impact Rating of 0.05” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at

Calyxt Company Profile

Calyxt, Inc is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics.

Insider Buying and Selling by Quarter for Calyxt (NASDAQ:CLXT)

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with's FREE daily email newsletter.

Leave a Reply